F16.18

Clinical Causes: Repeated or prolonged use of hallucinogenic substances such as LSD, psilocybin, DMT, or mescaline. Lack of awareness about the potential mental health impacts of hallucinogen use. Psychological factors such as stress, underlying mental health disorders, or a history of substance misuse. Availability and accessibility of hallucinogenic drugs in certain environments or communities. Social influences and peer pressure encouraging substance experimentation and continued use.

Key Symptoms: Visual or auditory hallucinations that may persist beyond the immediate intoxication period. Disorganized thinking or speech, making communication difficult. Panic attacks, paranoia, or intense feelings of fear or dread. Mood swings, agitation, and unpredictable behavior. Perceptual distortions, such as altered sense of time, space, or body image. Potential physical symptoms like dilated pupils, increased heart rate, or tremors (depending on the specific substance used). Possible development of psychosis or episodic hallucination episodes that resemble psychotic disorders.

Diagnosis Path: Diagnosis involves a comprehensive clinical assessment, including obtaining detailed substance use history, mental health evaluation, and ruling out other causes of hallucinations or psychosis. Healthcare providers may also perform physical examinations and laboratory tests to exclude other medical conditions. The diagnosis of ICD-10 F16.18 is made when there is clear evidence of hallucinogen abuse accompanied by other hallucinogen-induced disorders, related directly to substance use.

Treatment Protocols: Treatment typically involves a multidisciplinary approach. This may include detoxification in severe cases, psychotherapy to address underlying psychological issues, and support groups for substance abuse. Management of specific symptoms or disorders might involve medication or behavioral interventions. Long-term strategies focus on preventing relapse, managing co-occurring mental health conditions, and providing education about the risks of hallucinogen use. Reinforcing safety and mental health stability is crucial for recovery.